Tafinlar and Actinic keratosis - a phase IV clinical study of FDA data


Actinic keratosis is found among people who take Tafinlar, especially for people who are female, 40-49 old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Tafinlar and have Actinic keratosis. It is created by eHealthMe based on reports of 13,205 people who have side effects when taking Tafinlar from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Aug, 17, 2022

13,205 people reported to have side effects when taking Tafinlar.
Among them, 11 people (0.08%) have Actinic keratosis.

What is Tafinlar?

Tafinlar has active ingredients of dabrafenib mesylate. eHealthMe is studying from 11,375 Tafinlar users for its effectiveness, alternative drugs and more.

What is Actinic keratosis?

Actinic keratosis (skin disease due to sun exposure) is found to be associated with 1,347 drugs and 808 conditions by eHealthMe.

Number of Tafinlar and Actinic keratosis reports submitted per year:

Could Tafinlar cause Actinic keratosis?

Time on Tafinlar when people have Actinic keratosis *:

  • < 1 month: 50 %
  • 1 - 6 months: 25 %
  • 6 - 12 months: 25 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Actinic keratosis when taking Tafinlar *:

  • female: 77.78 %
  • male: 22.22 %

Age of people who have Actinic keratosis when taking Tafinlar *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 66.67 %
  • 50-59: 11.11 %
  • 60+: 22.22 %

Common drugs people take besides Tafinlar *:

  1. Mekinist: 2 people, 18.18%

Common side effects people have besides Actinic keratosis *:

  1. Fever: 7 people, 63.64%
  2. Oedema Peripheral (superficial swelling): 6 people, 54.55%
  3. Dizziness: 6 people, 54.55%
  4. Diarrhea: 6 people, 54.55%
  5. Headache (pain in head): 6 people, 54.55%
  6. Dermatitis Exfoliative (widespread scaling of the skin, often with itching (pruritus), skin redness (erythroderma), and hair loss): 6 people, 54.55%
  7. Joint Pain: 6 people, 54.55%
  8. Joint Stiffness: 6 people, 54.55%
  9. Tumor Associated Fever: 6 people, 54.55%
  10. Muscle Aches (muscle pain): 6 people, 54.55%

Common conditions people have *:

  1. Malignant Melanoma (skin cancer rises from melancytes): 7 people, 63.64%
  2. Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 3 people, 27.27%

* Approximation only. Some reports may have incomplete information.

Do you take Tafinlar and have Actinic keratosis?

Check whether Actinic keratosis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Actinic keratosis and when was it recovered:

Expand to all the drugs that have ingredients of dabrafenib mesylate:

Alternative drugs to, pros and cons of Tafinlar:

Common Tafinlar side effects:

Browse all side effects of Tafinlar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Actinic keratosis treatments and more:

COVID vaccines that are related to Actinic keratosis:

Common drugs associated with Actinic keratosis:

All the drugs that are associated with Actinic keratosis:

Common conditions associated with Actinic keratosis:

All the conditions that are associated with Actinic keratosis:

How the study uses the data?

The study uses data from the FDA. It is based on dabrafenib mesylate (the active ingredients of Tafinlar) and Tafinlar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: